Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ: AMPH )

38.27 -0.85 (-2.17%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Why the growth investor may take a look at NASDAQ:AMPH.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Exploring NASDAQ:AMPH's growth characteristics.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations 
Via Chartmill
NASDAQ:AMPH, an undervalued stock with good fundamentals.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. 
Via Chartmill
Delving into NASDAQ:AMPH's Growth Prospects.
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
Earnings Outlook For Amphastar Pharma
Via Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:AMPH.
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to. 
Via InvestorPlace
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued.
For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals. 
Via Chartmill
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition
Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... 
Via Benzinga
NASDAQ:AMPH is not too expensive for the growth it is showing.
Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. 
Via Chartmill
Why NASDAQ:AMPH is Poised for High Growth.
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
Should you consider NASDAQ:AMPH for growth investing?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.